Lowering Our Fair Value Estimate for Novo Nordisk on FX Movements
We still expect Novo to gain $65 billion of a $200 billion global GLP-1 market in diabetes and obesity by 2031.
We still expect Novo to gain $65 billion of a $200 billion global GLP-1 market in diabetes and obesity by 2031.
